Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the african-american heart failure trial

Anne L. Taylor, Michael L. Sabolinski, S. William Tam, Susan Ziesche, Jalal K. Ghali, W. Tad Archambault, Manuel Worcel, Jay N Cohn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT). In this analysis, we investigated treatment effects by age <65 or ≥65 years. Methods and Results: Time-to-event curves were produced by the Kaplan-Meier method. Hazard ratios were calculated with the Cox proportional hazards model. Baseline characteristics showed that patients ≥65 years old had less hypertensive and more ischemic HF, better quality of life (QoL) scores, higher plasma B-type natriuretic peptide and creatinine levels, and received less background neurohormonal therapy. Kaplan-Meier curves showed that FDC I/H improved mortality and event-free survival in elderly patients. The hazard ratios for mortality, first heart failure hospitalization, and event-free survival (both unadjusted and adjusted for baseline differences), were similar quantitatively and in direction of effect in both age groups. Conclusions: In A-HeFT, FDC I/H improved outcomes in HF patients aged <65 or ≥65 years, despite significant baseline differences between these age groups. Patients aged ≥65 years, a group at greater mortality risk, had the greatest survival benefit from FDC I/H.

Original languageEnglish (US)
Pages (from-to)600-606
Number of pages7
JournalJournal of Cardiac Failure
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2012

Fingerprint

Isosorbide Dinitrate
Hydralazine
African Americans
Heart Failure
Disease-Free Survival
Mortality
Age Groups
Brain Natriuretic Peptide
Proportional Hazards Models
Creatinine
Hospitalization
Therapeutics
Quality of Life
Survival

Keywords

  • Heart failure
  • elderly subjects

Cite this

Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the african-american heart failure trial. / Taylor, Anne L.; Sabolinski, Michael L.; Tam, S. William; Ziesche, Susan; Ghali, Jalal K.; Archambault, W. Tad; Worcel, Manuel; Cohn, Jay N.

In: Journal of Cardiac Failure, Vol. 18, No. 8, 01.08.2012, p. 600-606.

Research output: Contribution to journalArticle

Taylor, Anne L. ; Sabolinski, Michael L. ; Tam, S. William ; Ziesche, Susan ; Ghali, Jalal K. ; Archambault, W. Tad ; Worcel, Manuel ; Cohn, Jay N. / Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the african-american heart failure trial. In: Journal of Cardiac Failure. 2012 ; Vol. 18, No. 8. pp. 600-606.
@article{5bb397a7c8514a8eb0698279eff833fe,
title = "Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the african-american heart failure trial",
abstract = "Background: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT). In this analysis, we investigated treatment effects by age <65 or ≥65 years. Methods and Results: Time-to-event curves were produced by the Kaplan-Meier method. Hazard ratios were calculated with the Cox proportional hazards model. Baseline characteristics showed that patients ≥65 years old had less hypertensive and more ischemic HF, better quality of life (QoL) scores, higher plasma B-type natriuretic peptide and creatinine levels, and received less background neurohormonal therapy. Kaplan-Meier curves showed that FDC I/H improved mortality and event-free survival in elderly patients. The hazard ratios for mortality, first heart failure hospitalization, and event-free survival (both unadjusted and adjusted for baseline differences), were similar quantitatively and in direction of effect in both age groups. Conclusions: In A-HeFT, FDC I/H improved outcomes in HF patients aged <65 or ≥65 years, despite significant baseline differences between these age groups. Patients aged ≥65 years, a group at greater mortality risk, had the greatest survival benefit from FDC I/H.",
keywords = "Heart failure, elderly subjects",
author = "Taylor, {Anne L.} and Sabolinski, {Michael L.} and Tam, {S. William} and Susan Ziesche and Ghali, {Jalal K.} and Archambault, {W. Tad} and Manuel Worcel and Cohn, {Jay N}",
year = "2012",
month = "8",
day = "1",
doi = "10.1016/j.cardfail.2012.06.526",
language = "English (US)",
volume = "18",
pages = "600--606",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "8",

}

TY - JOUR

T1 - Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the african-american heart failure trial

AU - Taylor, Anne L.

AU - Sabolinski, Michael L.

AU - Tam, S. William

AU - Ziesche, Susan

AU - Ghali, Jalal K.

AU - Archambault, W. Tad

AU - Worcel, Manuel

AU - Cohn, Jay N

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Background: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT). In this analysis, we investigated treatment effects by age <65 or ≥65 years. Methods and Results: Time-to-event curves were produced by the Kaplan-Meier method. Hazard ratios were calculated with the Cox proportional hazards model. Baseline characteristics showed that patients ≥65 years old had less hypertensive and more ischemic HF, better quality of life (QoL) scores, higher plasma B-type natriuretic peptide and creatinine levels, and received less background neurohormonal therapy. Kaplan-Meier curves showed that FDC I/H improved mortality and event-free survival in elderly patients. The hazard ratios for mortality, first heart failure hospitalization, and event-free survival (both unadjusted and adjusted for baseline differences), were similar quantitatively and in direction of effect in both age groups. Conclusions: In A-HeFT, FDC I/H improved outcomes in HF patients aged <65 or ≥65 years, despite significant baseline differences between these age groups. Patients aged ≥65 years, a group at greater mortality risk, had the greatest survival benefit from FDC I/H.

AB - Background: Fixed-dose combined isosorbide dinitrate/hydralazine (FDC I/H) significantly improved outcomes in patients with advanced heart failure (HF) receiving background neurohormonal therapy in the African-American Heart Failure Trial (A-HeFT). In this analysis, we investigated treatment effects by age <65 or ≥65 years. Methods and Results: Time-to-event curves were produced by the Kaplan-Meier method. Hazard ratios were calculated with the Cox proportional hazards model. Baseline characteristics showed that patients ≥65 years old had less hypertensive and more ischemic HF, better quality of life (QoL) scores, higher plasma B-type natriuretic peptide and creatinine levels, and received less background neurohormonal therapy. Kaplan-Meier curves showed that FDC I/H improved mortality and event-free survival in elderly patients. The hazard ratios for mortality, first heart failure hospitalization, and event-free survival (both unadjusted and adjusted for baseline differences), were similar quantitatively and in direction of effect in both age groups. Conclusions: In A-HeFT, FDC I/H improved outcomes in HF patients aged <65 or ≥65 years, despite significant baseline differences between these age groups. Patients aged ≥65 years, a group at greater mortality risk, had the greatest survival benefit from FDC I/H.

KW - Heart failure

KW - elderly subjects

UR - http://www.scopus.com/inward/record.url?scp=84864421166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864421166&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2012.06.526

DO - 10.1016/j.cardfail.2012.06.526

M3 - Article

VL - 18

SP - 600

EP - 606

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 8

ER -